Use of a new cardiac pacing mode designed to eliminate unnecessary ventricular pacing.
OBJECTIVE
To examine the performance of AAIsafeR2, a new pacing mode to minimize the cumulative proportion of ventricular pacing in patients who do not need regular ventricular support.


RESULTS
The safety of AAIsafeR2 was examined in 123 recipients (73 +/- 12 years old, 51% men) of dual chamber pacemakers implanted for sinus node dysfunction, paroxysmal AV block or the bradycardia-tachycardia syndrome. Data were collected from pacemaker diagnostics, and the first 43 patients underwent 24-h Holter recordings before being discharged from the hospital with AAIsafeR2 activated. No adverse event related to AAIsafeR2 was observed. All ventricular pauses detected on Holter tapes triggered immediate back-up ventricular pacing. Appropriate switches to DDD occurred in 97 of 123 patients. In 69 of 123 devices (56%) switches to DDD were non-sustained, and the average % ventricular pacing in this group was 0.2+/-0.5%.


CONCLUSIONS
AAIsafeR2 mode seems to be safe and reliable in patients with infrequent slowing or pauses in ventricular activity, while maintaining ventricular pacing below 1%.
Fröhlig
Gerd
G
Medizinische Universitatsklinik III, Universitätskliniken des Saarlandes Innere Medizin III, Homburg Germany. ingfro@uniklinikum-saarland.de
Gras
Daniel
D
Victor
Jacques
J
Mabo
Philippe
P
Galley
Daniel
D
Savouré
Arnaud
A
Jauvert
Gaël
G
Defaye
Pascal
P
Ducloux
Pascale
P
Amblard
Amel
A
D000368:Aged; D000369:Aged, 80 and over; D001145:Arrhythmias, Cardiac / Q000628:therapy*; D002304:Cardiac Pacing, Artificial / Q000009:adverse effects / Q000379:methods*; D015716:Electrocardiography, Ambulatory; D004869:Equipment Safety; D005260:Female; D005500:Follow-Up Studies; D006325:Heart Atria / Q000503:physiopathology; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010138:Pacemaker, Artificial; D012849:Sinoatrial Node / Q000503:physiopathology; D013577:Syndrome; D016896:Treatment Outcome